Navigation Links
Facet Solution's AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
Date:10/15/2007

LOGAN, Utah, Oct. 15 /PRNewswire/ -- Facet Solutions, Inc. announced today that it has completed one year follow-up on the first cohort of patients to receive its Anatomic Facet Replacement System (AFRS(TM)). The clinical outcomes for these patients at one year include a significant decline in leg and back pain; improved motion and function; and no post-operative complications. Additionally, the first patient in the AFRS(TM) study has completed the two year follow up evaluation with similarly positive results.

The AFRS(TM) has been developed by Facet Solutions, Inc. to provide patients with lumbar spinal stenosis and facet degeneration a motion preserving alternative to lumbar spinal fusion. The AFRS(TM) procedure includes replacing the diseased facet joint with an anatomic implant that restores the natural motion, stability, and balance to the lumbar spine.

An international team of Orthopedic surgeons began the initial AFRS(TM) study at the Hospital Servidor Publico Estadol in Sao Paulo in late September 2005. The team included Dr. Allen Carl of Albany Medical Center in Albany, New York and Dr. Carlos Oliveira of Sao Paulo, Brazil.

"I believe that the early clinical results for the AFRS(TM) clearly demonstrate that this new treatment option is improving the quality of life for my patients who would otherwise lose significant motion using current fusion or dynamic stabilization devices," Dr. Oliviera stated. "In fact, many of my patients were having fusions and would come back four and five years later needing a subsequent fusion at adjacent levels as a result of the reduction in motion at the original fused level of the spine. I anticipate that this technology will ultimately become the surgical standard of care for spinal stenosis patients in the future."

"Facet Solutions is very pleased with the early clinical experience," added Eric Bannon, VP of Clinical Affairs. "The company looks forward to expanding this clinical outcome data w
'/>"/>

SOURCE Facet Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. The many facets of milk and its health potential
2. The Multi-Faceted Chemical Benzene
3. Multifaceted Stress: Mere thought is stressful!
4. Solutions Being Sought For Prevention Of Rickets
5. Mental Hospitals Offer More Problems than Solutions
6. Sex Workers Adopt IT Solutions to Fight AIDS
7. Bilcare Signs Pact With Honeywell for Packaging Solutions
8. Planning for Good Health Resolutions
9. Simple Solutions to Postpartum Weight Retention
10. Solutions Possible for Providing Water and Sanitation in Poor Urban Settlements, Says WaterAid
11. Silicon eye implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
... survey, biting a bar of chocolate every day is co...h chocolates are high in fat and sugar, it has lon..., recent evidence suggests that, like other plant ...xidants, which can protect from chronic disease. ...
...tudy which suggests hormone suppression therapy co...ncer patient's chances of living free of the disea...y Hospital, examined the potential benefits of sup...e more commonly known male hormone testosterone, a...
... amount of fluids should be taken, in order to rep...er is far better than 'energy' drinks for keeping ...is maximum need for fluids,// henceforth, you'll b...ls topped up with regular drinks. There are a lot ...
...ch are protective substances, produced by the body...m kill the TB bacteria, researchers in the UK repo... journal Nature Medicine,// these heat-shock prote...body help cells survive stressful times and bolste...
Other Medicine News:Health News:Hormone Therapy applicable for Prostate Cancer 2
(Date:5/21/2008)... HILDEN, Germany, May 21 /...V Test as Front-line,Screen, Long-term data from ...Cancer show that women screened only with a human ...o develop moderate to severe cervical disease over...onal cytology (the Pap,"smear"). The research foll...
(Date:5/20/2008)...Statistically Significant Reduction of IBS Pain an...Effect Observed, SAN DIEGO, May 20 /...results of a recent Phase 2b study of its oral kap...onstrated statistically significant,results in the...adoline,produced significant improvement in diarrh...
(Date:5/20/2008)... 94 Percent of Men Maintained Normal Testosteron...Treatment 92 Percent of Men Expressed Sat...- Indevus,Pharmaceuticals, ... NEBIDO(R),(testosterone undecanoate), an investig...he treatment of hypogonadism, was presented in a l...
(Date:5/20/2008)...ata on Newly-Approved Cimzia(R) Presented at Diges...swire/ -- UCB announced today that data,presented ...sustainable,efficacy and safety of Cimzia(R) (cert...ts with moderate to severe Crohn,s disease. Data a...y of responders and the remission,rate remained st...
Breaking Medicine Technology:Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 2Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 3Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 4Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 2Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 3Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 4Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 2Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 5Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 6Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 7Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 8BLU MED Announces New Medical Preparedness Contracts 7283 1BLU MED Announces New Medical Preparedness Contracts 7283 2BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 1BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 2U S Patent 7 299 083 Awarded to Signalife 2023 1U S Patent 7 299 083 Awarded to Signalife 2023 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 1FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 3FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 4
...uture Pandemics , ,BETHESDA, Md., April 2, 2007--O...anish influenza pandemic is why it struck differen...cipalities such as,St. Louis spared the fate of th...emented similar public health measures? What made ...es funded by the,National Institutes of Health (NI...
...ent Therapy Significantly,Improved Absorption of F...y and DAYTON, Ohio, April 04, 2007 /PRNewswire/ --..., today unveiled,data from two phase III clinical ... formerly EUR-1008, for the treatment of,Exocrine ...ug,Administration (FDA) granted fast track status ...
Other Medicine Technology:Rapid Response was Crucial to Containing the 1918 Flu Pandemic 2Rapid Response was Crucial to Containing the 1918 Flu Pandemic 3Rapid Response was Crucial to Containing the 1918 Flu Pandemic 4Rapid Response was Crucial to Containing the 1918 Flu Pandemic 5Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety.
The 5500s electronic architecture incorporates advanced circuit designs optimized for efficiency and function. We call it HI VUE an engineering philosophy that directs the development of each subsys
The HI VISION 6500 high resolution digital ultrasound system offers advanced clinical imaging, enhanced operating efficiency, and remarkable clinical flexibility, all in robust and versatile configur
...features of the ELECTRA 1400C are designed to achi...away capabilities. This system includes automated ...nogen and factor assays in a single setup. It also...eparation of reference curves and patient sample d...
Medicine Products: